Research

Research

Two of the biggest challenges in treating advanced prostate cancer are varying responses and acquired resistance to antiandrogen therapy. We seek to understand the mechanisms of antiandrogen resistance, to identify novel biomarkers, and to develop therapeutic approaches to prevent or overcome resistance.

cartoon
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. (Mu P, Zhang Z, Benelli B et al. Science 355(6320):84-88)